Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08SJZ
|
|||
| Former ID |
DAP001022
|
|||
| Drug Name |
Ibandronate
|
|||
| Synonyms |
BFQ; Acid ibandronico; Ibandronic Acid; Bisphosphonate 2; R484; RPR 102289A; Bondronat (TN); Boniva (TN); Bonviva (TN); Ibandronic acid (INN); Ibandronic acid [INN:BAN]; RPR-102289A; Ibandronic acid, sodium salt, monohydrate; Roche brand of ibandronic acid, sodium salt, monohydrate; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid; [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID; (1-Hydroxy-3-(methylpentylamino)propylidene)diphosphonic acid; (1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate; 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Osteoporosis [ICD-11: FB83.0; ICD-10: M85.8; ICD-9: 733] | Approved | [1], [2] | |
| Therapeutic Class |
Bone Density Conservation Agents
|
|||
| Company |
Roche; GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H23NO7P2
|
|||
| Canonical SMILES |
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O
|
|||
| InChI |
1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
|
|||
| InChIKey |
MPBVHIBUJCELCL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 114084-78-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7843823, 7978906, 8187097, 10318381, 14899229, 17137086, 43118190, 46504766, 46508134, 46513034, 50067809, 50070897, 50352086, 57309756, 57314150, 85175518, 92309009, 92719342, 96024748, 103265985, 104321814, 117626546, 125338459, 126584244, 126628258, 126653235, 126670896, 128627634, 134338290, 135030117, 135603369, 135649664, 136990668, 137008722, 142216113, 151995142, 160964054, 162176651, 163122790, 163417770, 164787819, 172439442, 172854478, 175267950, 176484248, 177748834, 179149628, 196105630, 204371129, 210279677
|
|||
| ADReCS Drug ID | BADD_D01116 ; BADD_D01117 ; BADD_D02426 | |||
| SuperDrug ATC ID |
M05BA06
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Geranyltranstransferase (FDPS) | Target Info | Modulator | [3] |
| BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||
| Superpathway of cholesterol biosynthesis | ||||
| Trans, trans-farnesyl diphosphate biosynthesis | ||||
| Geranylgeranyldiphosphate biosynthesis | ||||
| KEGG Pathway | Terpenoid backbone biosynthesis | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Influenza A | ||||
| HTLV-I infection | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Cholesterol biosynthesis | |||
| Pathwhiz Pathway | Steroid Biosynthesis | |||
| Reactome | Cholesterol biosynthesis | |||
| Activation of gene expression by SREBF (SREBP) | ||||
| WikiPathways | Activation of Gene Expression by SREBP (SREBF) | |||
| SREBP signalling | ||||
| Cholesterol Biosynthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3059). | |||
| REF 2 | Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med. 2009 Feb;122(2 Suppl):S14-21. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.